There is a good chance you know someone who is affected by prostate cancer.
In 2020, an estimated 1.4 million men were diagnosed with prostate cancer. When prostate cancer advances to other body parts, it’s called mHSPC.
We spoke to Dr. Neal Shore, M.D. U.S. Chief Medical Officer of Urology/Surgical Oncology at Genesis Care:
“mHSPC stands for Metastatic Hormone-Sensitive Prostate Cancer. What that means is the cancer is outside the prostate. It could be in the bones, lungs, livers, or the soft tissues area we call lymph nodes.”
The good news is they have a host of combination-type therapies that can put this disease in remission, helping patients live years with prostate cancer.
mHSPC can often be treated with hormone therapy that inhibits testosterone, yet only 1 in 3 people diagnosed with mHSPC survive for five years or longer.
The most recent study is a trial called the Arasens Trial. The findings led to FDA approval for combining lowering the testosterone level, adding chemotherapy, and an oral medication known as an androgen receptor/inhibitor/blocker.
That medication is called NUBEQA®.
Dr. Shore says the new treatment brings optimism to those facing this severe diagnosis:
“Optimism is the key word. There’s no doubt about it; it’s not a pseudo-optimism. I have patients living years longer than they would have thought 10-15 years ago.”
Our ultimate goal is a permanent cure, but Dr. Shore wants to put the disease in a state of remission so patients can live a good life.
As always, it’s essential for anyone facing this diagnosis to consult with their doctor.
Speak with your healthcare provider, urologist, or any medical oncologist knowledgeable about the options. There are several options inclusive of mHSPC.
For more information on NUBEQA®, go to nubeqa-us.com.